A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : 4-HC / 4-hydroperoxycyclophosphamide

[Related PubMed/MEDLINE]
Total Number of Papers: 217
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   4-HC  (>> Co-occurring Abbreviation)
Long Form:   4-hydroperoxycyclophosphamide
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells. AML, Bu, Flu, HSCT
2021 Ameliorative effect of recombinant human lactoferrin on the premature ovarian failure in rats after cyclophosphamide treatments. GCs, HD, LD, MD, NC, POF, rhLF, ROS
2021 Ligustrazine alleviates cyclophosphamide-induced hepatotoxicity via the inhibition of Txnip/Trx/NF-kappaB pathway. CP, ELISA, NF-kappaB, Trx
2021 Peroxisome proliferator-activated receptor-γ signalling protects hair follicle stem cells from chemotherapy-induced apoptosis and epithelial-mesenchymal transition. EMT, HF, NAGED, pCIA, PPAR
2020 The protective effects of pretreatment with resveratrol in cyclophosphamide-induced rat ovarian granulosa cell injury: In vitro study. CY, GCs, RES
2019 Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. 5-FU, UFT
2019 The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway. 2-F-araA, LN, MCL, MKI67, PB, STAT5B
2018 Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. AML, Bu, DAC, FLT3-ITD
2018 Inhibitors of apoptosis protect the ovarian reserve from cyclophosphamide. c-PARP, CPA, p-AKT
10  2018 Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway. FLSs, MTX, P-gp, RA, RT-PCR
11  2016 Protective effect of Korean Red Ginseng against chemotherapeutic drug-induced premature catagen development assessed with human hair follicle organ culture model. CIA, KRG
12  2016 Short-term exposure of human ovarian follicles to cyclophosphamide metabolites seems to promote follicular activation in vitro. AMH, PM
13  2015 Cyclophosphamide-induced vasopressin-independent activation of aquaporin-2 in the rat kidney. AQP2, IMCD, NKCC2, NSIAD, V2R
14  2014 Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. EFS, LCLs, PM, SNPs
15  2012 Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells. CY
16  2011 The role of proximal nephron in cyclophosphamide-induced water retention: preliminary data. AQP1, AQP7, PTCs
17  2010 Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas. ABMT, CI, EFS, OS
18  2008 Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. CY, MCL, SCID
19  2007 Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. BSO, FSH, TUNEL
20  2007 Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy. HFs
21  2007 Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody. mAb, ROS, ssDNA, TUNEL, TUNEL
22  2007 The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. ---
23  2007 The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. 5-FU
24  2007 The role of autologous transplantation for acute myeloid leukemia in first and second remission. AML, APL, ASCT, ATRA, EFS
25  2006 Chemotherapy disrupts activity of translational regulatory proteins in bone marrow stromal cells. MMP-2
26  2006 Cyclophosphamide enhances TNF-alpha-induced apoptotic cell death in murine vascular endothelial cell. CPA
27  2006 Ex vivo expansion of mafosfamide-purged PBPC products. MF, rh, SRC, TPO
28  2006 Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry-based assay. ALDH, ALDH1A1, PI
29  2006 RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. ALDH1A1, ATRA, CP
30  2005 Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. ---
31  2005 [A retroviral bicistronic strategy for efficient coexpression of ALDH1 and mdr1]. FCM, G1Na-AIM, IRES, mdrl, PCR, VCR
32  2004 Adenosine triphosphate (ATP) enhances the antitumor effect of etoposide (VP16) in lung cancer cells. ATP
33  2004 Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway. 4-HDC, ADR, CY, FasL, MTX, OS
34  2004 Oxidative DNA damage induced by a hydroperoxide derivative of cyclophosphamide. 8-oxodG, CP
35  2004 Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. ALDH, ATRA
36  2003 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia. PBPCs
37  2003 Aldehyde-dehydrogenase gene-transduced hematopoietic cell line K562 overcomes the cytoxicity of cyclophosphamide in vitro. ---
38  2003 Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. ADR
39  2003 [Study on expression and resistance of the double drug resistance genes transduced into human umbilical cord blood CD34+ cells mediated by bicistronic retroviral vector]. ALDH1
40  2002 A bicistronic retroviral vector to introduce drug resistance genes into human umbilical cord blood CD34+ cells to improve combination chemotherapy tolerance. ALDH1, FACS, MTT, PCR, RT
41  2002 Purging in autologous hematopoietic stem cell transplantation using adenosine triphosphate (ATP) and 4-hydroperoxycyclophosphamide (4-HC). ATP, SPRM
42  2002 UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. ---
43  2002 [Electroporation-mediated gene transduction and expression of class 1 aldehyde dehydrogenase (ALDH1) and multidrug resistance gene (MDR1)]. RT, VCR
44  2002 [Improvement of combination chemotherapy tolerance of human umbilical cord blood CD(34)(+) cells transducted with double drug resistance genes by a bicistronic retroviral vector]. ALDH3, MACS
45  2001 Amelioration of the cytotoxic effects of chemotherapeutic agents by grape seed proanthocyanidin extract. GSPE, IDA
46  2001 Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. EDR
47  2001 Chemopreventive effects of grape seed proanthocyanidin extract on Chang liver cells. GSPE, IDA, RT-PCR
48  2001 DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. CLL
49  2001 Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide. ---
50  2001 Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. MTX
51  2001 Genetic modification of hematopoietic progenitor cells for combined resistance to 4-hydroperoxycyclophosphamide, vincristine, and daunorubicin. ALDH-3, MACS, MDR1, PBPC
52  2001 L-buthionine sulfoximine potentiates the antitumor effect of 4-hydroperoxycyclophosphamide when administered locally in a rat glioma model. BSO
53  2001 The cellular and molecular basis of health benefits of grape seed proanthocyanidin extract. GSPE, IDA
54  2001 The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. AML
55  2000 Camptothecin analogues with enhanced antitumor activity at acidic pH. CMMDC, CPT, MDC, TPT
56  2000 Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. BCNU, BG, CHO, CHOWTAGT, PM
57  2000 Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. ALDH1, AS
58  2000 Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma. ASCT, MAF
59  1999 Enhanced cytotoxic interaction between 5-fluorouracil and 4-hydroperoxycyclophosphamide against L1210 murine leukemic cells: applicability to ex vivo purging. 5-FU
60  1999 Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. 4-HCR, O6-BG
61  1999 Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2'-deoxyadenosine. B-CLL, CdA, CP, MAF
62  1999 Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy. ---
63  1999 Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity. 4-HDC, PM
64  1998 Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. ABMT, AML, DFS
65  1998 Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. ALDH1, G6PD
66  1998 Evidence for a critical role of DNA topoisomerase IIalpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line. topo IIalpha
67  1998 Ex vivo expansion of immature 4-hydroperoxycyclophosphamide-resistant progenitor cells from G-CSF-mobilized peripheral blood. CFUs, G-PBSC, GFmix, IL, LTC-ICs
68  1998 Fibronectin fragment-facilitated retroviral transfer of the glutathione-S-transferase pi gene into CD34+ cells to protect them against alkylating agents. AA, ADM, GST-pi
69  1998 In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. ALDH1
70  1998 Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. ---
71  1998 Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. CPT, topo I, TPT
72  1998 Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). FCA
73  1997 Increased growth inhibition of human chronic myelogenous leukemic cells by a combination of c-myb antisense oligonucleotide and 4-hydroxyperoxycyclophosphamide in vitro. CML
74  1997 Protection of hematopoietic progenitors from ultraviolet C by interleukin-1 and tumor necrosis factor-alpha. CFCs, IL-1, TNF-alpha, UVC
75  1997 [Hematopoietic stem cell transplantation for children with cancer]. BMT
76  1996 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement. BM, CR, NHL, OS, PR
77  1996 Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. BCNU, CI, TPT
78  1996 Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. ABMT, AML, CFU-GM
79  1996 Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon. alpha-IFN, CML, gamma-IFN
80  1996 Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. ---
81  1996 Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. CP, PM
82  1996 Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. ALDH1, PCR
83  1996 Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines. ICLs
84  1996 Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. ---
85  1996 Use of amifostine in bone marrow purging. ---
86  1995 Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. ABMT, MNC
87  1995 Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. CP, NB
88  1995 Effect of stem cell factor on myelopoiesis potential in human Dexter-type culture systems. mAb, SCF
89  1995 Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. ---
90  1995 Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex. ALAK, BM, BMT, NK, rIL-2, Roq
91  1995 Generation of human natural killer cells from pharmacologically purged bone marrow. ABMT, BM, NK
92  1995 Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. AML, Bu, CR, CY, TBI, TNC
93  1995 Interleukin-1 and tumor necrosis factor alpha induce class 1 aldehyde dehydrogenase mRNA and protein in bone marrow cells. ALDH1, DEAB, IL-1, TNF-alpha
94  1995 Interleukin-11 (IL-11) and IL-9 counteract the inhibitory activity of transforming growth factor beta 3 (TGF-beta 3) on human primitive hematopoietic progenitor cells. BM, GM-CSF, IL-11, TGF-beta 3
95  1995 Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release. ---
96  1995 Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line. ADH, ISCs, PM
97  1995 Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. ---
98  1995 Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. CFU-GM, PBPC
99  1995 The effects of interleukin-1 beta and tumor necrosis factor-alpha on in vitro colony formation by human hematopoietic progenitor cells exposed to doxorubicin or hydroquinone. BM, BMMNC, DX, HPC, HQ, IL-1beta, pHPC, TNF-alpha
100  1994 31P NMR spectroscopic studies of the effects of cyclophosphamide on perfused RIF-1 tumor cells. ---